NCT05152901View on ClinicalTrials.gov

Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

June 6, 2022

Study Completion Date

June 6, 2022

Conditions
Anaphylactic Reaction
Interventions
DRUG

EpiPen ®.

A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.

DRUG

Epinephrine (0.3mg) inhaled

Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2

DRUG

Epinephrine (1.3mg)

A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.

DRUG

Epinephrine (4mg)

A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Herston

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

De Motu Cordis

INDUSTRY

NCT05152901 - Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults | Biotech Hunter | Biotech Hunter